Search
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigationalCamizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally … [L64094,L64107] It binds the ligand binding domain of ERα, antagonizing ERα encoded by both wild-type and mutated *ESR1* and inducing proteasome-dependent degradation of the receptor without agonizing
Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor DegradersSelinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigational[L10145] The FDA approved Selinexor in June 2019. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at
Piflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalthe tissue is expressing the appropriate target protein. … Prostate cancer is the most common non-cutaneous malignancy affecting men in North America[A235344] - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent
P2X purinoceptor 4
go.drugbank.com/bio_entities/BE0005793TargetHumansPromotes the differentiation and activation of Th17 cells via expression of retinoic acid-related orphan receptor C/RORC (PubMed:35165166).
Synonyms: ATP receptor, Purinergic receptorP2Y purinoceptor 1
go.drugbank.com/bio_entities/BE0009816TargetHumansReceptor for extracellular adenine nucleotides such as ADP (PubMed:25822790, PubMed:9038354, PubMed:9442040).
Synonyms: ADP receptor, Purinergic receptorFunction: A1 adenosine receptor bindingCatumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnIts market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].
Exenatide
go.drugbank.com/drugs/DB01276ApprovedInvestigationalIt activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control[L42690]. … [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021.
Products: BYDUREON® BCISE® 2MG SUSPENSIÓN DE LIBERACIÓN PROLONGADAAlbiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnIt is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. … Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline).
Lornoxicam
go.drugbank.com/drugs/DB06725ApprovedInvestigationalLornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. … Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties.
Products: LORİXAM 8 MG IM/IV ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, 1 flakon+1 çözücü ampul ve 3 flakon+3 çözücü ampul, LORNOX 8 MG IM/IV ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETMeningococcal polysaccharide vaccine group C
go.drugbank.com/drugs/DB13890ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Mixtures: NIMENRIX 0,5 ML IM ENJEKSIYON ICIN TOZ ICEREN FLAKON VE COZUCU ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADET